GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » Debt-to-EBITDA

JBM (Healthcare) (HKSE:02161) Debt-to-EBITDA : 0.37 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

JBM (Healthcare)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was HK$82.1 Mil. JBM (Healthcare)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was HK$6.7 Mil. JBM (Healthcare)'s annualized EBITDA for the quarter that ended in Sep. 2024 was HK$242.6 Mil. JBM (Healthcare)'s annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for JBM (Healthcare)'s Debt-to-EBITDA or its related term are showing as below:

HKSE:02161' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.64   Med: 2.89   Max: 8.05
Current: 0.64

During the past 7 years, the highest Debt-to-EBITDA Ratio of JBM (Healthcare) was 8.05. The lowest was 0.64. And the median was 2.89.

HKSE:02161's Debt-to-EBITDA is ranked better than
68.75% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs HKSE:02161: 0.64

JBM (Healthcare) Debt-to-EBITDA Historical Data

The historical data trend for JBM (Healthcare)'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JBM (Healthcare) Debt-to-EBITDA Chart

JBM (Healthcare) Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial 5.14 2.89 2.51 1.40 0.61

JBM (Healthcare) Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 1.70 0.85 0.75 0.37

Competitive Comparison of JBM (Healthcare)'s Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JBM (Healthcare)'s Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where JBM (Healthcare)'s Debt-to-EBITDA falls into.



JBM (Healthcare) Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

JBM (Healthcare)'s Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(82.508 + 50.899) / 219.909
=0.61

JBM (Healthcare)'s annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(82.064 + 6.655) / 242.636
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2024) EBITDA data.


JBM (Healthcare)  (HKSE:02161) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


JBM (Healthcare) Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of JBM (Healthcare)'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


JBM (Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
Executives
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Sum Kwong Yip, Derek
Queenshill Development Limited
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited 2101 Beneficial owner
Gavett Limited 2201 Interest of corporation controlled by you
United Islands Group Limited 2201 Interest of corporation controlled by you
Fortstar Limited 2201 Interest of corporation controlled by you
Tao Richard 2201 Interest of corporation controlled by you
Hon Hing Tong Patricia 2202 Interest of your spouse
Tao Paul 2201 Interest of corporation controlled by you
Choi Siu Ping 2202 Interest of your spouse
Longjin Investments Limited 2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines